Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Cholinergic System Dysfunction and Neurodegenerative Diseases: Cause or Effect?
Labeling mesenchymal cells with DMSA-coated gold and iron oxide nanoparticles: assessment of biocompatibility and potential applications.
Oct4-induced oligodendrocyte progenitor cells enhance functional recovery in spinal cord injury model.
Application of multispectral imaging detects areas with neuronal myelin loss, without tissue labelling.
Rates of Adverse Events and Multiple Sclerosis Relapses Before and After Introduction of a Purported Generic Glatiramer Acetate in mexico: Results from a Large Patient Support Program in Mexico.
Advances of Molecular Imaging for Monitoring the Anatomical and Functional Architecture of the Olfactory System.
Spiritual wellbeing and perceived uncertainty in patients with multiple sclerosis in south-east Iran.
Autologous hematopoietic SCT normalizes miR-16, -155 and -142-3p expression in multiple sclerosis patients.
Directed Differentiation of Oligodendrocyte Progenitor Cells From Mouse Induced Pluripotent Stem Cells.
Lower urinary tract dysfunction in patients with multiple sclerosis.
From the periphery to the brain: Lipocalin-2, a friend or foe?
Naturally Occurring Antibodies as Therapeutics for Neurologic Disease : Can Human Monoclonal IgMs Replace the Limited Resource IVIG?
[Update of the treatment of multiple sclerosis].
New and emerging immune-targeted drugs for the treatment of multiple sclerosis.
Subcutaneous IgG in neurologic diseases.
Tropical myelopathies.
A Qualitative Study of Nutritional Behaviors in Adults With Multiple Sclerosis.
[Optic neuritis and optic ischemic neuropathy: the problem of differential diagnosis].
Disease modifying and antiangiogenic activity of 2-methoxyestradiol in a murine model of rheumatoid arthritis.
Multiple sclerosis: Managing patients in primary care.
Erythropoietin: new directions for the nervous system.
A Psychometric Validation of Two Brief Measures to Assess Palliative Need in Patients Severely Affected by Multiple Sclerosis.
MS, MRI, and the 2010 McDonald criteria: a Canadian expert commentary.
Microglial nodules in early multiple sclerosis white matter are associated with degenerating axons.
Regulation: The FDA is overcautious on consumer genomics.
Pages
« first
‹ previous
…
434
435
436
437
438
439
440
441
442
…
next ›
last »